AI assistant
Entera Bio Ltd. — Director's Dealing 2022
Jan 14, 2022
35604_dirs_2022-01-14_98cf2035-1d14-4351-a923-1ba64dd22d64.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Entera Bio Ltd. (ENTX)
CIK: 0001638097
Period of Report: 2022-01-01
Reporting Person: Galitzer Hillel (Chief Operating Officer)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Ordinary Shares, par value NIS 0.0000769 per share | 34106 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (right to buy) | $6.31 | 2023-11-15 | Ordinary Shares, par value NIS 0.0000769 per share (143000) | Direct | |
| Stock Option (right to buy) | $2.14 | 2030-03-16 | Ordinary Shares, par value NIS 0.0000769 per share (175000) | Direct | |
| Stock Option (right to buy) | $3.15 | 2031-04-21 | Ordinary Shares, par value NIS 0.0000769 per share (125000) | Direct |
Footnotes
F1: (1) The options vested ratably on a quarterly basis over a four-year period commencing on February 15, 2018.
F2: (2) The options vest over a four-year period that commenced on March 16, 2020, with 25% of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining three-year period.
F3: (3) The options vest over a four-year period that commenced on April 21, 2021, with 25% of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining three-year period.